Cytotoxicity of ferrocenyl-ethynyl phosphine metal complexes of gold and platinum

Anticancer Research

Volumn 31, Issue 3, 2011, Pages 825-829

  Fourie, Eleanor ^a   Erasmus, Elizabeth ^a   Swarts, Jannie C ^a   Jakob, Alex Ander ^b   Lang, Heinrich ^b   Joone, Gisela K ^c   Van Rensburg, Constance E J ^c  

^a UNIVERSITY OF THE FREE STATE   (South Africa)

^b CHEMNITZ UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Cytotoxicity; Ethynyl phosphine; Ferrocene; Gold; HeLa; Platinum

Indexed keywords

3(4,5 DIMETHYLTHIAZOL 2 YL)DIPHENYLTETRAZOLIUM BROMIDE; CISPLATIN; DYE; FERROCENE DERIVATIVE; FERROCENYL ETHYNYL; GOLD COMPLEX; PHOSPHINE; PLATINUM COMPLEX; RUTHENOCENYL ETHYNYL COMPLEX; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG ACTIVITY; HELA CELL; HUMAN; HUMAN CELL; IC 50; OXIDATION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ALKYNES; CELL DEATH; COORDINATION COMPLEXES; DRUG SCREENING ASSAYS, ANTITUMOR; FERROUS COMPOUNDS; GOLD; HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; OXIDATION-REDUCTION; PHOSPHINES; PLATINUM;

EID: 79956120210     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Maree MD, Neuse EW, Erasmus E and Swarts JC: Synthesis and anchoring of antineoplastic ferrocene and phthalocyanine derivatives on water-soluble polymeric drug carriers derived from lysine and aspartic acid. Met Based Drugs Article ID 217573, 2008: 1-10, 2008. doi:10.1155/2008/217573.
2. Gale GR, Atins LM, Meischen SJ, Smith AB and Walker EM: Chemotherapy of advanced L1210 leukemia with platinum compounds in combination with other antitumor agents. Cancer Treat Rep 61: 445-450, 1977. (Pubitemid 8137947)
3. Ringsdorf H: Structure and properties of pharmacologically active polymers. J Polym Sci Symp 51: 135-153, 1975.
4. Swarts JC, Swarts DM, Maree DM, Neuse EW, La Madeleine C and Van Lier J: Poly aspartamides as water-soluble drug carriers Part 1: Antineoplastic activity of ferrocene-containing polyaspartamide conjugates. Anticancer Res 21: 2033-3037, 2001.
5. Sharman WM, Allen CM and Van Lier JE: Photodynamic therapeutics: basic principles and clinical applications. Drug Discov Today 44: 507-517, 1999. (Pubitemid 29497854)
6. Köpf-Maier P, Köpf H and Neuse EW: Ferricenium complexes: a new type of water-soluble antitumor agent. J Cancer Res Clin Oncol 108: 336-340, 1984. (Pubitemid 15211814)
7. Ward JM, Grabin ME, Berlin E and Young DM: Prevention of renal failure in rats receiving cis-diamminedichloroplatinum(II) by administration of furosemide. Cancer Res 37: 1238-1240, 1977. (Pubitemid 8088155)
8. Neuse EW and Kanzawa F: Evaluation of the activity of some water-soluble ferrocene and ferricenium compounds against carcinoma of the lung by the human tumor clonogenic assay. Appl Organomet Chem 4: 19-26, 1990.
9. Shago RF, Swarts JC and Van Rensburg CEJ: Antineoplastic activity of a series of ferrocene-containing alcohols. Anticancer Res 27: 3431-3433, 2007. (Pubitemid 47607572)
10. Swarts JC, Vosloo TG, Cronje SJ, Du Plessis WC, Van Rensburg CEJ, Kreft E and Van Lier JE: Cytotoxicity of a series of ferrocene-containing beta-diketones. Anticancer Res 28: 2781-2784, 2008.
11. Osella D, Ferrali M, Zanello P, Laschi F, Fontani M, Nervi C and Carvigiolio G: On the mechanism of the antitumour activity of ferrocenium derivatives. Inorg Chim Acta 306: 42-48, 2000.
12. Epton R, Hobson ME and Marr G: Oxidation of ferrocene and substituted ferrocenes in the presence of horseradish peroxidase. J Organomet Chem 149: 231-244, 1978.
13. Pladziewicz JR and Carney MJ: Reduction of ferricenium ion by horse heart ferrocytochrome-c. J Am Chem Soc 104: 3544-3545, 1982.
14. Carlson BW, Grodkowski J, Miller LL and Neta P: Oxidation of NADH involving rate-limiting one-electron transfer. J Am Chem Soc 106: 7233-7239, 1984.
15. Pladziewicz JR, Rodeberg DA, Likar MD and Brenner MS: Kinetic study of the oxidation of spinach plastocyanine by ferrocenium ion derivatives. Inorg Chem 24: 1450-1453, 1985.
16. Pladziewicz JR, Abrahamson AJ, Davis RA and Likar MD: Kinetics of the oxidation of high-potential iron sulfur protein from chromatium by ferrocenium derivatives. Inorg Chem 26: 2058-2062, 1987.
17. Liu A, Leese DN, Swarts JC and Sykes AG: Reduction of Escherichia coli ribonucleotide reductase subunit R2 with eight water-soluble ferrocene derivatives. Inorg Chim Acta 337: 83-90, 2002.
18. Swarts JC, Aquino MAS, Lam KY and Sykes AG: Kinetic studies on the reduction of the tyrosil radical of the R2 subunit of E. coli ribonucleotide reductase. Biochim Biophys Acta 1247: 215-224, 1995.
19. Swarts JC and Sykes AG: Towards an understanding of the reactivity of E. coli R2 ribonucleotide reductase: a mechanistic approach to inactivation. Anticancer Drug Des 9: 41-50, 1994.
20. Han JY, Swarts JC and Sykes AG: Kinetic studies on the hydrazine and Phenylhydrazine reductions of the Escherichia coli R2 subunit of ribonucleotide reductase. Inorg Chem 35: 4629-4634, 1996.
21. Nyholm S, Thelander L and Gräslund A: Reduction and loss of the iron center in the reaction of the small subunit of mouse ribonucleotide reductase with hydroxyurea. Biochem 32: 11569-11574, 1993.
22. Artin E, Wang J, Lohman GJS, Yokoyama K, Yu G, Griffin RG, Bar G and Stubbe J: Insight into the mechanism of inactivation of ribonucleotide reductase by gemcitabine 5′-diphosphate in the presence or absence of reductant. Biochem 48: 11622-11629, 2009.
23. Jakob A, Ecorchard P, Linseis M, Winter RF and Lang H: Synthesis, solid state structure and spectro-electrochemistry of ferrocene-ethynyl phosphine and phosphine oxide transition metal complexes. J Organomet Chem 694: 655-666, 2009.
24. Van Rensburg CEJ, Jooné GK and O'SuIlivan JF: Tetramethylpiperidine-substitution increases the antitumor activity of the aminophenazines for an acquired multidrug- resistant cell line. Anticancer Drug Des 15: 303-306, 2000. (Pubitemid 32096157)
25. Neuse EW: Synthetic polymers as drug-delivery vehicles in medicine. Met Based Drugs Article ID 469531, 2008: 1-19, 2008. doi:10.1155/2008/469531.